Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L DeMets

Showing results (21-30 of 98) with videos related to

Pageof 10
Sort By:
Journal of Clinical Epidemiology|July 14, 2020
Achieving effective informed oversight by DMCs in COVID clinical trialsDavid L DeMets, Thomas R Fleming
Clinical Trials (London, England)|June 16, 2006
An Institutional Review Board dilemma: responsible for safety monitoring but not in controlDavid L DeMets, Norman Fost, Madison Powers
Biometrics|March 23, 2004
Design and analysis of group sequential clinical trials with multiple primary endpointsMichael R Kosorok, Shi Yuanjun, David L DeMets
Statistics in Medicine|September 27, 2002
Monitoring clinical trials: issues and controversies regarding confidentialityThomas R Fleming, Susan Ellenberg, David L DeMets
Biostatistics (Oxford, England)|June 22, 2017
Discussion: The role, position, and function of the FDA-The past, present, and futureThomas R Fleming, David L Demets, Lisa M McShane
Journal of Allergy and Infectious Diseases|January 10, 2022
Monitoring clinical trials in infectious diseasesDavid L DeMets, Thomas R Fleming, Susan S Ellenberg
JAMA|July 15, 2010
Bias and trials stopped early for benefitSusan S Ellenberg, David L DeMets, Thomas R Fleming
Clinical Trials (London, England)|April 10, 2018
Data Monitoring Committees: Current issuesThomas R Fleming, Susan S Ellenberg, David L DeMets
JAMA|February 28, 2020
When Can Intermediate Outcomes Be Used as Surrogate Outcomes?David L DeMets, Bruce M Psaty, Thomas R Fleming
Clinical Trials (London, England)|March 30, 2024
Society for Clinical Trials Data Monitoring Committee initiative website: Closing the gapDavid L DeMets, Susan Halabi, Lehana Thabane, et al.
Pageof 10

Showing results (21-30 of 98) with videos related to

Sort By:
Pageof 10
Journal of Clinical Epidemiology|July 14, 2020
Achieving effective informed oversight by DMCs in COVID clinical trialsDavid L DeMets, Thomas R Fleming
Clinical Trials (London, England)|June 16, 2006
An Institutional Review Board dilemma: responsible for safety monitoring but not in controlDavid L DeMets, Norman Fost, Madison Powers
Biometrics|March 23, 2004
Design and analysis of group sequential clinical trials with multiple primary endpointsMichael R Kosorok, Shi Yuanjun, David L DeMets
Statistics in Medicine|September 27, 2002
Monitoring clinical trials: issues and controversies regarding confidentialityThomas R Fleming, Susan Ellenberg, David L DeMets
Biostatistics (Oxford, England)|June 22, 2017
Discussion: The role, position, and function of the FDA-The past, present, and futureThomas R Fleming, David L Demets, Lisa M McShane
Journal of Allergy and Infectious Diseases|January 10, 2022
Monitoring clinical trials in infectious diseasesDavid L DeMets, Thomas R Fleming, Susan S Ellenberg
JAMA|July 15, 2010
Bias and trials stopped early for benefitSusan S Ellenberg, David L DeMets, Thomas R Fleming
Clinical Trials (London, England)|April 10, 2018
Data Monitoring Committees: Current issuesThomas R Fleming, Susan S Ellenberg, David L DeMets
JAMA|February 28, 2020
When Can Intermediate Outcomes Be Used as Surrogate Outcomes?David L DeMets, Bruce M Psaty, Thomas R Fleming
Clinical Trials (London, England)|March 30, 2024
Society for Clinical Trials Data Monitoring Committee initiative website: Closing the gapDavid L DeMets, Susan Halabi, Lehana Thabane, et al.
Pageof 10